Owning the genome: A moral analysis of DNA patenting

Owning the Genome: A Moral Analysis of DNA Patenting

Volumn , Issue , 2004, Pages 1-235

  Resnik, David B ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896219167     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (397)

1. Adams, L. et al. 1999. Method for determining the presence of mutated BRCA protein. U. S. Patent 5, 965, 377. Washington, DC: U. S. Patent and Trademark Office.
2. Adams, M. et al. 2000. The genome sequence of drosophila melanogaster. Science 287:2185-95.
3. Alfred Bell & Co. v Catalda Fine Arts. 191 F. 2d 99 (2nd Cir. 1951).
4. American Heritage Dictionary of the English Language. 4th ed. 2000. New York: Houghton Mifflin.
5. American Society of Human Genetics (ASHG). 1991. Position paper on patenting of expressed sequence tags. Washington, DC: American Society of Human Genetics.
6. Anderson, E. 1990. Is women's labor a commodity? Philosophy and Public Affairs 19, no. 1:71-92.
7. Andre, J. 1992. Blocked exchanges: A taxonomy. Ethics 103, no. 1:29-47.
8. Andrews, E. 1995. Religious leaders prepare to fight patents on genes. New York Times, 13 May, N1, L1.
9. Andrews, L., and D. Nelkin. 2001. Body bazaar. New York: Crown Publishers.
10. Annas, G. 2000. Rules for research on human genetic variation: Lessons from Iceland. Journal of the American Medical Association 342:1830-33.
11. Application of Nelson. 280 F. 2d 172, 175 (Cust. & Pat. App. 1960).
12. Audi, R. 2001. The architecture of reason. New York: Oxford University Press.
13. Ayala, F. 1982. Population and evolutionary genetics. Menlo Park, CA: Benjamin Cummings.
14. Baggot, B. 1998. Human gene therapy patents in the United States. Human Gene Therapy 9, no. 1:151-57.
15. Baier, A. 1984. For the sake of future generations. In Earthbound, edited by T. Reagan. New York: Random House.
16. Baier, K. 1958. The moral point of view. Ithaca, NY: Cornell University Press.
17. Baker v Selden. 101 U. S. 99 (1879).
18. Balter, M. 2000. France rebels against gene-patenting law. Science 288:2115.
19. -. 2001. Tranatlantic war over BRCA1 patent. Science 292:1818.
20. Barron, J., and C. Dienes. 1999. Constitutional law. St. Paul, MN: West Group.
21. Barboza, D. 2000. Suburban genetics: Scientists searching for a perfect lawn. New York Times, 8 July, A1.
22. Barinaga, M. 1999. No winners in patent shootout. Science 284:1752-53.
23. Barton, J. 2000. Reforming the patent system. Science 287:1933-34.
24. Barton, J., and P. Berger. 2001. Patenting agriculture. Issues in Science and Technology Online 17, no. 4(Summer): http://www.nap.edu/issues/17.4/p- barton.htm. Accessed: 15 February 2002.
25. Beardsley, T. 1994. Big-time biology. Scientific American 271, no. 5:90-94.
26. Benn, S. 1967. Property. In Encyclopedia of philosophy, edited by P. Edwards. New York: Macmillan.
27. Berenson, A., and N. Wade. 2000. A call for sharing of research causes gene stocks to fall. New York Times, 15 March, A1.
28. Berg, P. 1975. Summary statement of the Asilomar conference on recombinant DNA molecules. Proceedings of the National Academy of Sciences 72:1981-84.
29. Berman, H., D. Goodsell, and P. Bourne. 2002. Protein structures: From famine to feast. American Scientist 90:350-59.
30. Bernat, J., C. Culver, and B. Gert. 1982. Defining death in theory and practice. Hastings Center Report 12, no. 1:5-8.
31. Biotechnology Industry Organization (BIO). 2000. Primer: Genomic and genetic research, patent protection, and twenty-first century medicine. Washington, DC: Biotechnology Industry Organization.
32. -. 2001a. The economic contributions of the biotechnology industry to the U. S. economy. Washington, DC: Biotechnology Industry Organization.
33. -. 2001b. State government initiatives in biotechnology in 2001. Washington, DC: Biotechnology Industry Organization.
34. Black's Law Dictionary. 7th ed. 1999. St. Paul, MN: West Group.
35. Blaug, M. 1980. The methodology of economics. Cambridge: Cambridge University Press.
36. Blumenthal, D., E. Campbell, N. Causino, and K. Louis. 1996. Participation of lifescience faculty in relationships with industry. New England Journal of Medicine 335:1734-39.
37. Blumenthal, D., E. Campbell, M. Anderson, N. Causino, and K. Louis. 1997. Withholding research results in academic life science: Evidence from a national survey of faculty. Journal of the American Medical Association 277:1224-28.
38. Bodenheimer, T. 2000. Conflict of interest in clinical drug trials: A risk factor for scientific misconduct. Paper presented at sthe Office of Human Research Protections conference on conficts of interest in research, Washington, DC, 15 August.
39. Broad, W., and N. Wade. 1993. Betrayers of truth. 2nd ed. New York: Simon and Schuster.
40. Brody, B. 1999. Protecting human dignity and the patenting of human genes. In perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
41. Brunner, E. 1947. The divine imperative. Philadelphia: Westminster Press.
42. Burke, J. 1995. The day the universe changed. Boston: Little, Brown.
43. Butler, D., and T. Reichhardt. 1999. Long-term effects of GM crops serves up food for thought. Nature 398:651-56.
44. Cahil, L. 2001. Genetics, commodification, and social justice in the globalization era. Kennedy Institute for Ethics Journal 11, no. 3:221-38.
45. Calamari, J., and J. Perillo. 1998. The law of contracts. 4th ed. St. Paul, MN: West Group.
46. Campbell, E. 2002. Personal communication, 23 January.
47. Campbell, E., B. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N. Holtzman, and D. Blumenthal. 2002. Data withholding in academic genetics: Evidence from a national survey. Journal of the American Medical Association 287:473-80.
48. Caplan, A., and J. Merz. 1996. Patenting gene sequences: Not in the best interests of science or society. British Medical Journal 312:926.
49. Caulfield, T., and R. Gold. 2000a. Genetic testing, ethical concerns, and the role of patent law. Clinical Genetics 57:370-75.
50. -. 2000b. Whistling in the wind. Forum for Applied Research and Public Policy 15, no. 1:75-80.
51. Celera Genomics. 2001. Celera web page. www.celera.com. Accessed: 1 July 2001.
52. Chakrabarty, A. 1981. Microorganisms having multiple compatible degradative energy-generating plasmids and preparation thereof. U. S. Patent 4, 259, 444. Washington, DC: U. S. Patent and Trademark Office.
53. Chan, A., K. Chong, C. Martinovich, C. Simerly, and G. Schatten. 2001. Transgenic monkeys produced by retroviral gene transfer into mature oocytes. Science 291:309-12.
54. Chapman, L., and E. Bloom. 2001. Clinical xenotransplantation. Journal of the American Medical Assocation 285:2304-6.
55. Chea, T. 2002. Litter of gene-altered pigs cloned. Washington Post, 3 January, A1.
56. Christian Century. 1995. Call for a moratorium on gene patenting. Christian Century 112, no. 20:633-34.
57. Churchill, L. 1999. The United States health care system under managed care: How the commodification of health care distorts ethics and threatens equity. Health Care Analysis 7:393-411.
58. Claverie, J. 2001. What if there are only 30, 000 human genes? Science 291:1255-57.
59. Clayton, E., K. Steinberg, M. Khoury, E. Thomson, L. Andrews, M. Kahn, L. Kopelman, and J. Weiss. 1995. Informed consent for stored tissue samples. Journal of the American Medical Association 274:1786-92.
60. Cohen, S. 1999. Selling bits and pieces of humans to make babies. Journal of Medicine and Philosophy 24:288-306.
61. Cohen, S., and H. Boyer. 1980. Process for producing biologically functional molecular chimeras. U. S. Patent 4, 237, 224.
62. Cole-Turner, R. 1997. Genes, religion, and society: The developing views of the churches. Science and Engineering Ethics 3:273-88.
63. -. 1999. Personal communication. 15 July 1999.
64. Collins, F., and V. McKusick. 2001. Implications of the human genome project for medical science. Journal of the American Medical Association 285:540-44.
65. Copi, I. 1986. Introduction to logic, 7th ed. New York: Macmillan.
66. Council on Ethical and Judicial Affairs, American Medical Association (AMA). 1997. Patenting the human genome. Chicago: American Medical Association.
67. -. 1998. Current opinions with annotations. Chicago: American Medical Association.
68. Council for Responsible Genetics (CRG). 2000. The genetic bill of rights. Cambridge, MA: Council for Responsible Genetics.
69. Cranor, C. 2001. Learning from law to address uncertainty in the precautionary principle. Science and Engineering Ethics 7, no. 3:313-26.
70. Crespi, R. 2000. An analysis of moral issues affecting patenting inventions in the life sciences: A European perspective. Science and Engineering Ethics 6, no. 2:157-80.
71. Crigger, B. 1995. The vampire project. Hastings Center Report 25, no. 1:2.
72. Daniels, N. 1984. Just health care. Cambridge: Cambridge University Press.
73. Dastgheib-Vinarov, S. 2000. A higher nonobviousness standard for gene patents: Protecting biomedical research from the big chill. Marquette Intellectual Property Law Review 4:143-79.
74. Davidson, R. 1986. Source of funding and outcome of clinical trials. Journal of General Internal Medicine 1:155-58.
75. De Angelis, C. 2000. Conflict of interest and the public trust. Journal of the American Medical Association 284:2237-38.
76. Dellar v Samuel Goldwyn, Inc. 104 F. 2d 661, 662 (C. A.2 1939).
77. Derwent Information. 2001a. Frequently asked questions. http://www.derwent.com/. Accessed: 20 April 20.
78. -. 2001b. Glossary of patent terms. http://www.derwent.com/. Accessed: 20 April.
79. Diamond, J., L. Levine, and M. Madden. 2000. Understanding torts. 2nd ed. New York: Lexis Publishing.
80. Diamond v Chakrabarty, 447 U. S. 303 (1980).
81. Doll, J. 1998. The patenting of DNA. Science 280:689-90.
82. -. 2000. Personal communication. 1 September 2001.
83. Dreyfuss, R. 1989. General overview of the intellectual property system. In Owning scientific and technical information, edited by V. Weil and J. Snapper. New Brunswick, NJ: Rutgers University Press.
84. -. 2000. Collaborative research: Conflicts on authorship, ownership, and accountability. Vanderbilt Law Review 53:1161-1232.
85. Dreyfuss, R., and R. Kwal. 1996. Intellectual property. Westbury, NY: Foundation Press.
86. Earman J. 1992. Bayes or bust? Cambridge: MIT Press.
87. Eastman Kodak Co. v Image Technical Services, Inc. 112 S. Ct. 2072 (U. S. Cal. 1992).
88. Eisenberg, R. 1990. Patenting the human genome. Emory Law Journal 39:721-45.
89. -. 1995. Patenting organisms. Encyclopedia of bioethics. Revised ed. New York: Simon and Schuster.
90. -. 1997. Structure and function in gene patenting. Nature Genetics 15, no. 2:125-30.
91. Englehart, T. 1996. The foundations of bioethics. 2nd ed. New York: Oxford University Press.
92. Enriquez, J. 1998. Genomics and the world's economy. Science 281:925-26.
93. Enserink, M. 1999. GM crops in cross hairs. Science 286:1662-68.
94. -. 2000. Patent office may raise the bar on gene claims. Science 287:1196-97.
95. European Commission. 1998. Opinions of the group of advisors on the ethical implications of biotechnology of the European Commission. Brussels: European Commission.
96. -. 2000. Communication from the commission on the precautionary principle. Brussels: European Commission.
97. -. 2001. The role of the European Commission. http://europa.eu.int/comm/ role-en.htm#1. Accessed: 1 June 2001.
98. European Parliament and Council. 1998. Directive 98/44/EC on the legal protection of biotechnological inventions. Official Journal L 213, 30(July):13-21.
99. European Patent Convention (EPC). 1998. Convention on the grant of European patents. Munich: European Patent Convention.
100. Evans, J. 1999. The uneven playing field on the dialogue on patenting. In Perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
101. Eweson, S. 1976. Apparatus for making organic fertilizer. U. S. Patent 3, 930, 799. Washington, DC: U. S. Patent and Trademark Office.
102. Ex Parte Hibberd et al. 227 United States Patent Quarterly 443 (1985).
103. Feinberg, J. 1973. Social philosophy. Englewood Cliffs, NJ: Prentice-Hall.
104. Feinman, J. 2000. Law 101. New York: Oxford University Press.
105. Feist Publications Inc. v Rural Telephone Service Co., Inc. 499 U. S. 340 (1991).
106. Fields, S. 2001. Proteomics in genomeland. Science 291:1221-24.
107. Finkel, E., D. Malakoff, M. Balter, and A. Lawler. 2002. Patenting fight, round 2. Science 295:1621.
108. Fisher, L. 1999. The race to cash in on the genetic code. New York Times, 29 August, A1.
109. Florida Prepaid Postsecondary Ed. Expenses Bd. v College Savings Bank. 527 U. S. 627 (1999).
110. Fons, M. 2000. The intellectual property landscape in the field of plasmid-based gene therapy. Journal of Drug Targets 7:407-11.
111. Foster, F., and R. Shook. 1993. Patents, copyrights, and trademarks. 2nd ed. New York: John Wiley.
112. Foster, F., P. Vecchia, and M. Repacholi. 2000. Science and the precautionary principle. Science 288:979-81.
113. Fox, D., and T. Paul. 1999. The "EST" dilemma: Should the discovery of a part of a gene lead to a patent that could cover the entire gene once discovered? Health Law News 13, no. 2:7.
114. Fox, R., and J. De Marco. 1990. Moral reasoning. Chicago: Holt, Rinehart and Winston.
115. Foubister V. 2000. Gene patents raise concerns for researchers, clinicians. American Medical News (21 February): 1-4.
116. Frankena, W. 1973. Ethics. 2nd ed. Englewood Cliffs, NJ: Prentice-Hall.
117. Funk Brothers Seed Co. v Kalo Inoculant Co. 333 U. S. 127 (1948).
118. Gabriel, S. et al. 2002. The structure of haplotype blocks in the human genome. Science 296:2225-29.
119. Ganeri, A. 1997. Religions explained. New York: Henry Holt.
120. Gardner, W., and J. Rosenbaum. 1998. Database protection and access to information. Science 281:786-87.
121. Garfinkle, A. 1981. Forms of explanation. New Haven, CT: Yale University Press.
122. Garris, J. 1996. The case for patenting medical procedures. American Journal of Law and Medicine 22, no. 1:85-108.
123. Gellhorn, E., and W. Kovacic. 1994. Antitrust law and economics. 4th ed. St. Paul, MN: West Group.
124. Gelsinger Complaint. 2002. http://www.sskrplaw.com/links/healthcare2. html. Accessed: 15 August 2002.
125. Genentech Inc. v Chiron Corp. 112 F. 3d 495 (U. S. App. Ct., Fed. Cir. 1997).
126. Genetic Alliance. 2000. Statement submitted on gene patenting. Subcommittee on Courts and Intellectual Property, U. S. House of Representatives hearing on gene patents and other genomic inventions, 13 July 13.
127. Gibbard, A. 1990. Wise choices, apt feelings. Cambridge: Harvard University Press.
128. -. 1998. Which of our genes make us human? Science 281:1432-34.
129. Gibbs, W. 1996. The price of silence: Does profit-minded secrecy retard scientific progress? Scientific American 275, no. 5:15-16.
130. -. 1997. Plantibodies: How human antibodies produced by field crops enter clinical trials. Scientific American 277, no. 5:44.
131. Gill, M., and R. Sade. 2002. Paying for kidneys: The case against prohibition. Kennedy Institute of Ethics Journal 12, no. 1:17-45.
132. Gitter, D. 2001. International conflicts over patenting human DNA sequences in the United States and the European Union: An argument for compulsory licensing and a fair-use exemption. New York University Law Review 76:1623-89.
133. Glendon, M. 1991. Rights talk. New York: Free Press.
134. Gold, E. 1996. Body parts: Property rights and the ownership of human biological materials. Washington, DC: Georgetown University Press.
135. Gold, E., and T. Caulefield. 2002. The moral tollbooth: A method that makes use of the patent system to address ethical concerns in biotechnology. Lancet 359:2268-70.
136. Goldhammer, A. 2001. Current issues in clinical research and the development of pharmaceuticals. Accountability in Research 8:283-92.
137. Goozner, M. 2000. The price isn't right. American Prospect 11, no. 20:1.
138. Gorovitz, S. et al. 1979. Philosophical analysis. 3rd ed. New York: Random House.
139. Gosselin, P., and P. Jacobs. 2000. Patent office now at heart of debate. Los Angeles Times, 7 February, A1.
140. Graham v John Deere Co. 383 U. S. 1, 17-18 (1966).
141. Green, R. 2001. What does it mean to use someone as a means only: Rereading Kant. Kennedy Institute of Ethics Journal 11, no. 3:247-61.
142. Greenberg v Miami Children's Hosp. Research Institute, Inc. 2002 WL 1483266. (N. D. Ill. 2002).
143. Guenin, L. 1996. Norms for patents concerning human and other life forms. Theoretical Medicine 17:279-314.
144. Gura, T. 2001. After a setback, gene therapy progresses... gingerly. Science 291:1692-97.
145. Gutmann, A., and D. Thompson. 1996. Democracy and disagreement. Cambridge, MA: Harvard University Press.
146. Hamlyn, D. 1984. Metaphysics. Cambridge: Cambridge University Press.
147. Hanson, M. 1997. Religious voices in biotechnology: The case of gene patenting. Hastings Center Report 27, no. 6(Special Supplement):1-21.
148. -. 1999. Biotechnology and commodification within health care. Journal of Medicine and Philosophy 24, no. 3:267-87.
149. Hegel, F. 1976. [1821]. The philosophy of the right. Knox, T (trans.). Oxford: Oxford University Press.
150. Heller, M., and R. Eisenberg. 1998. Can patents deter innovation? The anticommons in biomedical research. Science 280:698-701.
151. Henry, M., M. Cho, M. Weaver, and J. Merz. 2002. DNA patenting and licensing. Science 297:1279.
152. Hess, D. 1999. Suppression, bias, and selection in science: The case of cancer research. Accountability in Research 6, no. 4:245-57.
153. Hettinger, E. 1989. Justifying intellectual property. Philosophy and Public Affairs 18:31-52.
154. Hill, T. 1992. Dignity and practical reason in kant's moral theory. Ithaca, NY: Cornell University Press.
155. Hoedemaekers, R., and W. Dekkers. 2002. Is there a unique moral status of human DNA that prevents patenting? Kennedy Institute of Ethics Journal 11, no. 4:359-86.
156. Holy Bible (King James Version). 1997. Nashville, TN: Thomas Nelson.
157. Honore, A. 1977. Ownership. In The nature and process of law, edited by P. Smith. New York: Oxford University Press.
158. Hughes, S. 2001. Making dollars out of DNA: The first major patent in biotechnology and the commercialization of molecular biology, 1974-1980. Isis 92:541-75.
159. Human Genome Organization (HUGO). 1995. Statement on the patenting of DNA sequences. Bethesda, MD: Human Genome Organization.
160. -. 2000. Statement on benefit sharing. Bethesda, MD: Human Genome Organization.
161. Human Genome Project. 2001. The science behind the human genome project. www.ornl.gov/hgmis/project/info.html. Accessed: 7 May 2001.
162. In re Deuel. 34 U. S. Pat. Quart. 1210 (2d Fed. Circ. 1995).
163. In re T. A. C. P. 609 S. 2d 588 (Florida 1992).
164. In re Wiggins. 488 F. 2d 538 (Cust. and Pat. App. 1973).
165. Israel, J., and W. La Fave. 1993. Criminal procedure. 5th ed. St. Paul, MN: West Group.
166. Jacob, M. 1997. Scientific culture and the making of the industrial west. New York: Oxford University Press.
167. Jacobson, M. et al. 1991. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. British Medical Journal 302:73-78.
168. Joint Appeal against Human and Animal Patenting. 1995. Press Conference Text. Washington, DC: Board of Church and Society of the United Methodist Church, 17 May.
169. Juengst, E. 1998. Should we treat the human germ-line as a global human resource? In Germ-line intervention and our responsibilities to future generations, edited by E. Agius E. and S. Busuttil. London: Kluwer Academic Press.
170. Juengst, E., and M. Fossel. 2000. The ethics of ES cells-Now and forever, cells without end. Journal of the American Medical Association 284:3180-84.
171. Kahane, H. 1990. Logic and philosophy: A modern introduction. 6th ed. Belmont, CA: Wadsworth.
172. Kahn, P. 1998. Coming to terms with genes and risk. Science 274:496-500.
173. Kamm, F. 1996. Morality, mortality. Vol. 1 & 2. New York: Oxford University Press.
174. Kant, I. [1785] 1981. Groundwork of the metaphysic of morals. Translated by J. Ellington. Reprint, Indianapolis, IN: Hackett Publishing.
175. Kantorovich, A. 1993. Scientific discovery. Albany, NY: State University of New York Press.
176. Karp, J. 1991. Experimental use as patent infringement: The impropriety of broad exemption. Yale Law Journal 100:2169-88.
177. Kass, L. 1985. Toward a more natural science: Biology and human affairs. New York: Free Press.
178. Kaufman, S. 1993. The origins of order. New York: Oxford University Press.
179. Kevles, D. 2001. Patenting life: A historical overview of law, interests, and ethics. Paper prepared for Yale Legal Theory Workshop. Available at: http://www.yale. edu/law/ltw/papers/ltw-kevles.pdf. Accessed: 22 August 2002.
180. Kevles, D., and A. Berkowitz. 2001. The gene patenting controversy: A convergence of law, economic interests, and ethics. Brooklyn Law Review 67:233-48.
181. Kimbrell, A. 1997. The human body shop. Washington, DC: Gateway.
182. Kitcher, P. 1993. The advancement of science. New York: Oxford University Press.
183. -. 1997. The lives to come. New York: Simon and Schuster.
184. Kiwanee Oil Co. v Bicron Corp. 416 U. S. 470, 480 (1974).
185. Kleyn, P., and E. Vesell. 1998. Genetic variation as a guide to drug development. Science 281:1820-21.
186. Knoppers, M. 1999. Status, sale, and patenting of human genetic material: An international survey. Nature Genetics 22:23-26.
187. Knoppers, B., M. Hirtle, and K. Glass. 1999. Commercialization of genetic research and public policy. Science 286:2277-78.
188. Ko, Y. 1992. An economic analysis of biotechnology patent protection. Yale Law Journal 102:777-802.
189. Kolata, G. 2000. Who owns your genes? New York Times, 15 May, A1.
190. Korn, D. 2000. Conflict of interest in biomedical research. Journal of the American Medical Association 284:2234-37.
191. Korsgaard, C. 1996. The sources of normativity. Cambridge: Cambridge University Press.
192. Kosso, P. 1992. Reading the book of nature. Cambridge: Cambridge University Press.
193. Krimsky, S., L. Rothenberg, P. Stott, and G. Kyle. 1996. Financial interests of authors in scientific publications. Science and Engineering Ethics 2, no. 4:395-410.
194. Kuflik, A. 1989. Moral foundations of intellectual property rights. In Owning scientific and technical information, edited by V. Weil and J. Snapper. New Brunswick, NJ: Rutgers University Press.
195. Kuhn, T. 1962. The structure of scientific revolutions. Chicago: University of Chicago Press.
196. Lafollette, N., and N. Shanks. 1996. Brute science: Dilemmas of animal experimentation. New York: Routledge.
197. Land, R., and B. Mitchell. 1996. Patenting life: No. First Things 63(May):20-22.
198. Langreth, R., and B. Davis. 2000. Press briefing set off rout in biotech. Wall Street Journal, 16 March, A19.
199. Lao, M. 1999. Unilateral refusals to sell or license intellectual property and the antitrust duty to deal. Cornell Journal of Law and Public Policy 9:193-219.
200. Laudan, L. 1978. Progress and its problems. Berkeley: University of California Press.
201. Leonard, D. 1999. The future of molecular genetic testing. Clinical Chemistry 45:726-31.
202. Locke, J. [1764] 1980. Second treatise of government. Reprint, Indianapolis, IN: Hackett.
203. Looney, B. 1994. Should genes be patented? The gene patenting controversy: Legal, ethical, and policy foundations of an international agreement. Law and Policy in International Business 26:231-72.
204. Lucotte, G., and F. Baneyx. 1993. Introduction to molecular cloning techniques. New York: VCH Publishers.
205. Lyons, D., ed. 1979. Rights. Belmont, CA: Wadsworth.
206. Mackie, J. 1977. Ethics: Inventing right and wrong. London: Penguin Books.
207. Malakoff, D. 2000. The rise of the mouse, biomedicine's model animal. Science 288:48-53.
208. Malakoff, D., and E. Marshall. 1999. NIH wins big as Congress lumps together eight bills. Science 282:598.
209. Marshall, E. 1997. Snipping away at genome patenting. Science 277:1752-53.
210. -. 1999a. Drug firms to create public database of genetic mutations. Science 284:406-7.
211. -. 1999b. A high-stakes gamble on genome sequencing. Science 284:1906-9.
212. -. 1999c. Legal fights over patents on life. Science 294:2067-68.
213. -. 2000a. Patent on HIV receptor provokes outcry. Science 287:1375-77.
214. -. 2000b. Talks of public-private deal end in acrimony. Science 287:1723-24.
215. -. 2000c. A deluge of patents creates legal hassles for research. Science 288:255-57.
216. -. 2000d. Claim and counterclaim on the human genome. Science 288:242-43.
217. -. 2000e. In the crossfire: Collins on genomes, patents, and rivalry. Science 287:2396-98.
218. -. 2000f. Gene therapy on trial. Science 288:951-57.
219. -. 2001. Sharing the glory, not the credit. Science 291:1189-93.
220. Marx, K. [1867] 1996. Das Kapital. Reprint, New York: Regnery Publishing.
221. Marx, K., and F. Engels. [1848] 1998. The communist manifesto. Reprint, New York: Signet Books.
222. Maughan, J., F. Lewis, and V. Smith. 2001. An introduction to arrays. Journal of Pathology 195, no. 1:3-6.
223. Mayr, E. 1982. The growth of biological thought. Cambridge: Harvard University Press.
224. Mazer v Stein. 347 U. S. 201 (1954).
225. McCrary, V. et al. 2000. A national survey of policies of disclosure of conflict of interest in biomedical research. New England Journal of Medicine 343:1621-26.
226. McDowell, N. 2002. Africa hungry for traditional food as biotech row drags on. Nature 418:571-72.
227. McQueen, M. 1998. Ethical and legal issues in the procurement, storage and use of DNA. Clinical chemistry and laboratory medicine 36:545-49.
228. Meadows, J. 1992. The great scientists. New York: Oxford University Press.
229. Mehlman, M., and J. Botkin. 1998. Access to the genome. Washington, DC: Georgetown University Press.
230. Merck & Co., Inc. v Olin Mathieson Chemical Corporation. 253 F. 2d 156 (4th Circ. 1958).
231. Merz, J. 2000. Statement submitted on gene patenting. Subcommittee on courts and intellectual property. U. S. House of Representatives hearing on gene patents and other genomic inventions, 13 July.
232. Merz, J., and M. Cho. 1998. Disease genes are not patentable: A rebuttal to McGee. Cambridge Quarterly of Healthcare Ethics 7:425-28.
233. Merz, J., M. Cho, M. Robertson, and D. Leonard. 1997. Disease gene patenting is bad innovation. Molecular Diagnosis 2, no. 4:299-304.
234. Merz, J., D. Magnus, M. Cho, and A. Caplan. 2002. Protecting subjects' interests in genetics research. American Journal of Human Genetics 71, no. 4:965-71.
235. Mill, J. [1859] 1956. On liberty. Reprint, New York: Liberal Arts Press.
236. -. [1861] 1979. Utilitarianism. Reprint, Indianapolis, IN: Hackett.
237. Miller, A., and M. Davis. 2000. Intellectual property: Patents, trademarks, and copyright. St. Paul, MN: West Group.
238. Mitchell, C. 1999. A Southern Baptist looks at patenting life. In Perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
239. Moore v Regents of the University of California. 793 P.2d 479 (Cal. 1990).
240. Morelli, M. 1999. Commerce in organs: A Kantian critique. Journal of Social Philosophy 30:315-24.
241. Morin, K. et al. 2002. Managing conflicts of interest in the conduct of clinical trials. Journal of the American Medical Association 287:78-84.
242. Morreim, H. 1995. Balancing act: The new medical ethics of medicine's new economics. Washington, DC: Georgetown University Press.
243. Munthe, C., and S. Welin. 1996. The morality of scientific openness. Science and Engineering Ethics 2, no. 4:411-28.
244. Murray, T. 1986. Who owns the body? On the ethics of using human tissue for commercial purposes. IRB: A Review of Human Subjects Research 8, no. 1:1-5.
245. Nader, R. 2000. Nader 2000 http://www.votenader.org/issues/agriculture- policy.html. Accessed: 6 November.
246. Nagel, E. 1977. Teleology revisited. Journal of Philosophy 74:261-302.
247. National Academy of Sciences (NAS). 1996. Guide for the care and use of laboratory animals. Washington, DC: National Academy of Sciences.
248. -. 2002. Animal biotechnology: Identifying science-based concerns. Washington, DC: National Academy Press.
249. National Commission for the Protection of Human Subjects in Biomedical and Behavioral Research. 1979. The Belmont report. Washington, DC: National Commission for the Protection of Human Subjects in Biomedical and Behavioral Research.
250. National Bioethics Advisory Commission (NBAC). 1998. Research involving human biological materials: Ethical issues and policy guidance. Washington, DC: National Bioethics Advisory Commission.
251. National Institutes of Health (NIH). 2001. Press Release for the FY 2002 President's Budget." Bethesda, MD: National Institutes of Health.
252. -. 2002. Press Release for FY 2003 President's Budget. Bethesda, MD: National Institutes of Health.
253. Nelkin, D., and L. Andrews. 1998. Homo economicus: The commercialization of body tissue in the age of biotechnology. Hastings Center Report 28, no. 5:30-39.
254. Nelkin, D., and S. Lindee. 1995. The DNA mystique. New York: Free Press.
255. Nelson, G., ed. 2001. Genetically modified organisms in agriculture: Economics and politics. New York: Academic Press.
256. Nestle, M. 2001. Food biotechnology: Whose values, whose decisions? Witness (May): 15-17.
257. Newton-Smith, W. 1981. The rationality of science. London: Routledge.
258. Nickel, L. 1976. Ripening of sugarcane by use of certain alcoholic and ethoxylated compounds. U. S. Patent 3, 930, 840. Washington, DC: U. S. Patent and Trademark Office.
259. Niiniluoto, I. 1999. Critical scientific realism. New York: Oxford University Press.
260. Normile, D. 2000. Monsanto donates its share of golden rice. Science 289:843-44.
261. Nozick, R. 1974. Anarchy, state, utopia. New York: Basic Books.
262. Nuffield Council on Bioethics. 2002. The ethics of patenting DNA. London: Nuffield Council.
263. Olson, R. 1967. Deontological ethics. In Encyclopedia of Philosophy. Vol. 1 & 2. Edited by P. Edwards. New York: Macmillan.
264. O'Neill, O. 1996. Towards justice and virtue: A constructive account of practical reason. Cambridge: Cambridge University Press.
265. Ossario, P. 1999. Common heritage arguments and the patenting of DNA. In Perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
266. Paabo, S. 2001. The human genome and our view of ourselves. Science 291:1219-20.
267. Pabst, P. 1999. Gene therapy and tissue engineering patents abound. Tissue Engineering 5, no. 1:79.
268. Parens, E. 1996. Taking behavioral genetics seriously. Hastings Center Report 26, no. 4:13-18.
269. Parker v Flook. 437 U. S. 584 (1978).
270. Patent and Trademark Office (PTO). 1999. Revised utility examination guidelines. Federal Register (21 December) 64, no. 244:71440-42.
271. -. 2001. General information regarding patents. Washington, DC: Patent and Trademark Office.
272. -. 2002. Patent search. www.uspto.gov. Accessed: 17 January 2002.
273. Pearl, J. 2000. Causality. Cambridge: Cambridge University Press.
274. Peltonen, L., and V. McKusick. 2001. Dissecting human disease in the postgenomic era. Science 291:1224-29.
275. Pennisi, E. 2000a. Stealth genome rocks researchers. Science 288:239-40.
276. -. 2000b. Fruit fly genome yields data and validation. Science 287:1374.
277. Peters, T. 1997. Playing God. New York: Routledge.
278. Pinstrup-Andersen, P., and E. Schioler. 2001. Seeds of contention: World hunger and the global controversy over GM (genetically modified) crops. Baltimore, MD: Johns Hopkins University Press.
279. Plant Variety Protection Act. 1994. 7 U. S. C. 2401.
280. Pojman, L. 1995. Ethics. 2nd ed. Belmont, CA: Wadsworth.
281. Poland, S. 2000. Genes, patents, and bioethics: Will history repeat itself? Kennedy Institute of Ethics Journal 10, no. 3:265-81.
282. Pollack, A. 2002. Genome pioneer will start center of his own. New York Times, 16 August, C1.
283. Popper, K. 1959. The logic of scientific discovery. London: Hutchinson.
284. Porter, R. 1997. The greatest benefit of mankind. New York: W. W. Norton.
285. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. 1981. Defining death. Washington, DC: President's Commission.
286. President's Council on Bioethics. 2002. Human cloning and human dignity: An ethical inquiry. Washington, DC: President's Council on Bioethics.
287. Price, S., and L. Wilson. 1982. Pathophysiology. 2nd ed. New York: McGraw-Hill.
288. Public Health Service (PHS). 2000. Draft interim guidance: Financial relationships in clinical research. Washington, DC: Public Health Service.
289. Rachels, J. 1993. The elements of moral philosophy. 2nd ed. New York: McGraw-Hill.
290. Radin, M. 1996. Contested commodities. Cambridge: Harvard University Press.
291. Rawls, J. 1971. A theory of justice. Cambridge: Harvard University Press.
292. -. 1993. Political liberalism. New York: Columbia University Press.
293. Regents of the University of California v Eli Lilly and Co. 119 F. 3d 1159 (U. S. Ct. App. Fed. Cir. 1997)
294. Reichhardt, T. 1998. Patent on gene fragment sends researchers a mixed message. Nature 396:499.
295. Reiss, M., and R. Straughan. 1996. Improving nature? The science and ethics of genetic engineering. Cambridge: Cambridge University Press.
296. Resnik, D. 1993. Do scientific aims justify methodological rules? Erkenntnis 38:223-32.
297. -. 1996. Basic research and corporate responsibility. Business and Society Review 96:57-59.
298. -. 1997. The morality of human gene patents. Kennedy Institute of Ethics Journal 7, no. 1:43-61.
299. -. 1998a. The commodification of human reproductive materials. Journal of Medical Ethics 24:388-93.
300. -. 1998b. The ethics of science. New York: Routledge.
301. -. 1998c. Industry sponsored research: Secrecy versus corporate responsibility. Business and Society Review 99:31-34.
302. -. 1999a. Privatized biomedical research, public fears, and the hazards of government regulation: Lessons from stem cell research. Health Care Analysis 7:273-87.
303. -. 1999b. The human genome diversity project: Ethical problems and solutions. Politics and the Life Sciences 18, no. 1:15-23.
304. -. 1999c. Scientific rationality and epistemic goals. Protosoziologie 12:258-89.
305. -. 2000. Financial interests and research bias. Perspectives on Science 8, no. 3:255-85.
306. -. 2001a. DNA patents and scientific discovery and innovation: Assessing benefits and risks. Science and Engineering Ethics 7, no. 1:29-62.
307. -. 2001b. DNA patents and human dignity. Journal of Law, Medicine, and Ethics 29, 2:152.
308. -. 2001c. Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Developing World Bioethics 1, no. 1:11-32.
309. -. 2001d. Regulating the market for human eggs. Bioethics 15, no. 1:1-25.
310. -. 2002a. Discoveries, inventions, and gene patents. In Who owns the life? edited by D. Magnus. New York: Prometheus Press.
311. -. 2003a. Is the precautionary principle unscientific? Studies in the History and Philosophy of the Biological Sciences 34:327-44.
312. -. 2003b. Exploitation in biomedical research. Theoretical Medicine and Bioethics 24:233-59.
313. Resnik, D., and K. De Ville. 2002. Bioterroism and patent rights: Compulsory licensure and the case of Cipro. American Journal of Bioethics 2, no. 3:29-39.
314. Resnik, D., and A. Shamoo. 2002. Conflict of interest and the university. Accountability in Research 9, no. 1:45-64.
315. Resnik, D., H. Steinkraus, and P. Langer. 1999. Human germline gene therapy. Austin, TX: RG Landes.
316. Resnik, M. 1987. Choices: An introduction to decision theory. Minneapolis: University of Minnesota Press.
317. Reynolds, T. 2000. Gene patent race speeds ahead amid controversy, concern. Journal of the National Cancer Institute, 92, no. 3:184-86.
318. Rifkin, J. 1983. Algeny. New York: Penguin Books.
319. -. 1985. Declaration of a heretic. London: Routledge and Kegan Paul.
320. -. 1998. The biotech century. New York: Penguin Putnam.
321. -. 2000. Personal communication, 17 July 2000.
322. Risjord, M. 2000. Woodcutters and witchcraft. Albany, NY: State University of New York Press.
323. Roberts, L. 2000. SNP mappers confront reality and find it daunting. Science 287:1898-99.
324. -. 2001. Controversial from the start. Science 291:1182-88.
325. Roberts, R. et al. 2001. Building a "Genbank" of the published literature. Science 291:2318-19.
326. Robertson, M., ed. 1994. Molecular biology of the cell. New York: Garland Publishing.
327. Roch Products v Bolar Pharmaceutical Co. 733 F. 2d 858 (Fed. Cir. 1984).
328. Rodwin, M. 1993. Medicine, money and morals. New York: Oxford University Press.
329. Rohwer, C., and A. Skrocki. 2000. Contracts. 5th ed. St. Paul: West Group.
330. Rollin, B. 1995. The Frankenstein syndrome. Cambridge: Cambridge University Press.
331. Rolston, H. 1994. Conserving natural value. New York: Columbia University Press.
332. Rosenberg, A. 1985. The philosophy of biology. Cambridge: Cambridge University Press.
333. -. 1995. The philosophy of social science. 2nd ed. Boulder, CO: Westview Press.
334. Ross, W. 1930. The right and the good. Oxford: Clarendon Press.
335. Rothstein, M., ed. 1997. Genetic secrets. New Haven, CT: Yale University Press.
336. Sackett, D., S. Straus, W. Richardson, W. Rosenberg, and B. Hayes. 1997. Evidencebased medicine. New York: Churchill Livingstone.
337. Sagoff, M. 1999. DNA patents: Making ends meet. In Perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
338. Samuelson, P. 1980. Economics. 11th ed. New York: McGraw-Hill.
339. Saunders, J., and C. O'Malley, eds. and trans. 1982. The anatomical drawings of Andreas Vesalius. New York: Bonanza Books.
340. Schatz, G. 1998. The Swiss to vote on gene technology. Science 281:1810-11.
341. Scheffler, S. 1988. Consequentialism and its critics. Oxford: Oxford University Press.
342. Schissel, A., J. Merz, and M. Cho. 1999. Survey confirms fears about licensing of genetic tests. Nature 402:118.
343. Schonmann, A. 1998. The patenting challenges of gene discovery. Nature Biotechnology 16(Supplement):47.
344. Scott, R. 2000. Testimony before the House Judiciary Subcommittee on courts and intellectual property, 13 July.
345. Service, R. 2000. Can Celera do it again? Science 287:2138-39.
346. -. 2001. Gene and proteins patents get ready to go head to head. Science 294:2082-83.
347. Shand, H. 1999. Terminator technology: Genetically altered seeds will destroy both diversity and good-producing capacity. Christian Social Action (October): 7-13.
348. Shattuck-Eidens, D. et al. 1997. Linked breast and ovarian cancer susceptibility gene. U. S. Patent 5, 693, 473. Washington, DC: U. S. Patent and Trademark Office.
349. Sharp, R., and M. Foster. 2001. Involving study populations in the review of research. Journal of Law, Medicine and Ethics 28, no. 1:41-49.
350. Shiva, V. 1996. Biopiracy: The plunder of nature and knowledge. Boston: South End Press.
351. Shoemaker, R. et al. 2001. Economic issues in agricultural biotechnology. Washington, DC: U. S. Department of Agriculture.
352. Shrader-Frechette, K. 1991. Risk and rationality. Berkeley: University of California Press.
353. Skyrms, B. 1985. Choice and chance. Belmont, CA: Wadsworth.
354. Smith, A. [1776] 1991. The wealth of nations. New York: Prometheus Books.
355. Smith, W. 2001. The culture of death. New York: Encounter Books.
356. Skolnick, M. et al. 1998. 170-linked breast and ovarian cancer susceptibility gene. U. S. Patent 5, 753, 441. Washington, DC: U. S. Patent and Trademark Office.
357. Stolberg, S., and J. Gerth. 2000. Medicine merchants: Holding down the competition. New York Times, 23 July, A1.
358. Sturges, M. 1997. Who should hold property rights to the human genome? An application of the common heritage of mankind. American University International Review 13:219-61.
359. Subramanian, G., M. Adams, J. Venter, and S. Broder. 2001. Implications of the human genome for understanding human biology and medicine. Journal of the American Medical Association 286:2296-2307.
360. Suzuki, D., and P. Knudtson. 1989. Genethics: The clash between the new genetics and human values. Cambridge: Harvard University Press.
361. Svatos, M. 1996. Biotechnology and the utilitarian argument for patents. Social Philosophy and Policy 13:113-44.
362. Swisher, K., ed. 1995. What is sexual harassment? San Diego, CA: Greenhaven Press.
363. Taubes, G. 1995. Scientists attacked for patenting Pacific tribe. Science 270:1112.
364. Telecomm Technical Services, Inc. v Siemens Rolm Communications, Inc. 150 F. Supp. 2d 1365 (N. D. Ga. 2000).
365. Time Magazine, March 9, 1981.
366. Tribble, J. 1998. Gene patents-A pharmaceutical perspective. Cambridge Quarterly of Healthcare Ethics 7:429-32.
367. United Kingdom Patent Office (UKPO). 2001. Five hundred years of patents. London: United Kingdom Patent Office.
368. United Nations Educational, Scientific and Cultural Organization (UNESCO). 1997. Universal Declaration on the Human Genome and Human Rights. Geneva: United Nations Educational, Scientific and Cultural Organization.
369. United States v Carroll Towing Co. 159 F. 2d 169 (2d Circuit 1947).
370. United States v White Motor Co. 194 F. Supp. 562 (D. C. Ohio 1961).
371. U. S. Constitution. Article 1, Section 8, Clause 8 (1787).
372. U. S. Department of Agriculture (USDA). 2001. Economic issues in agricultural biotechnology. Washington, DC: U. S. Department of Agriculture.
373. U. S. Patent Act. 1995. 35 U. S. C. 101.
374. Vacchiano, E. 1999. It's a wonderful genome: The written description requirement protects the human genome from overly broad patents. John Marshall Law Review 32:805-32.
375. Venter, C. et al. 2001. The sequence of the human genome. Science 291:1304-51.
376. Volti, R. 1995. Society and technological change. 3rd ed. New York: St. Martin's Press.
377. Wade, N. 2000a. Analysis of genome is said to be complete. New York Times, 7 April, A1.
378. -. 2000b. Rivals in race to decode human DNA agree to cooperate. New York Times, 22 June, A1.
379. -. 2000c. Genetic code of human life is cracked by scientist. New York Times, 27 June, A1.
380. Waldron, J. 1988. The right to private property. Oxford: Clarendon Press.
381. Walter, J. 1982. Principles of disease. Philadelphia: W. B. Saunders.
382. Walters, L., and J. Palmer. 1997. The ethics of human gene therapy. New York: Oxford University Press.
383. Walzer, M. 1983. Spheres of justice. New York: Basic Books.
384. Wambugu, F. 1999. Why Africa needs agricultural biotech. Nature 400:15-16.
385. Warner-Jenkinson Co. v Hilton Davis Chemical Co. 520 U. S. 17 (1997).
386. Wertheimer, R. 1996. Exploitation. Princeton, NJ: Princeton University Press.
387. Whittemore v Cutter. 29 F. Ca. 1120 (C. C. D. Mass. 1813).
388. Wicklegren, I. 1999. Mining the genome for drugs. Science 285:998-1001.
389. -. 2000. Mutation points way to salt recycling pathway. Science 289:23-26.
390. Wilmut, I. 1998. Cloning for medicine. Scientific American 279 no. 6:58-63.
391. Wong, D. 1997. The ABCs of gene cloning. New York: Chapman and Hall.
392. Wood, R., M. Mitchell, J. Sgouros, and T. Lindahl. 2001. Human DNA repair genes. Science 291:1284-89.
393. Woollett, G., and O. Hammond. 1999. An industry perspective on the gene patenting debate. In Perspectives on gene patenting, edited by A. Chapman. Washington, DC: American Association for the Advancement of Science.
394. World Medical Association. 2001. Declaration of Helsinki. Journal of the American Medical Association 284:3043-46.
395. Wynia, M., S. Latham, A. Kao, J. Berg, and L. Emmanuel. 1999. Medical professionalism in society. New England Journal of Medicine 341:1612-16.
396. Yaphe, J., R. Edman, B. Knishkowy, and J. Herman. 2001. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Family Practice 18, no. 6:565-68.
397. Zurer, P. 1994. NIH drops bid to patent gene fragments. Chemical and Engineering News 72, no. 8:5-6.